CRMD: CorMedix Inc. Growth-Adjusted Market Cap to Net Income

Symbol and logo of brand CorMedix Therapeutics (CRMD)

The valuation-to-earnings growth ratio reflects market sentiment, with the indicator currently at 0.00. CorMedix Inc. (CRMD) has solidified a positive image thanks to the success of Defencath. The brand is renowned for developing innovative tools to protect dialysis patients. The product's uniqueness in combating catheter-related infections has secured the company a protected niche within therapeutic centers.

CRMD (cormedix.com) PEG Multiple history from 07/04/2022 to 11/13/2026

Analytical breakdowns for CorMedix Inc. (CRMD)

- share price and consensus valuation forecast:
Price Performance Chart CorMedix Inc|CRMD - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization CorMedix Corp|CRMD - Total Company Value
- company book value details:
Equity per Share CorMedix|CRMD - Book Capitalization|Market Capitalization to Net Assets cormedix.com|CRMD - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Capital CorMedix Inc.|CRMD - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio cormedix.com|CRMD - Company Total Debt|Debt to Book Capital CorMedix Corp|CRMD - Company Long-Term Debts|Short-Term Debt Volume CorMedix|Immediate Liquidity cormedix.com
- net income and valuation multiples indicators:
CRMD - Company Net Income|Net Profit Forecast CorMedix Inc.|CRMD - Price to Earnings Ratio|Market Cap to Projected Earnings CorMedix Therapeutics|CRMD - PEG Multiple|Enterprise Value to EBITDA Ratio CorMedix Corp|CRMD - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months CorMedix|CRMD - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months cormedix.com|CRMD - Earnings per share growth in current year|Expected earnings per share growth for next year CorMedix Inc.
Summary company analytics:CorMedix Inc
Mass-produced product of CorMedix

Strategic alliances between CorMedix Inc. (CRMD) and dialysis centers to implement antimicrobial systems create a foundation for scaling, which is reflected in the company's P/E ratio and growth rates. This indicator divides the price-to-earnings ratio by the annual earnings growth percentage: a value below one signals that the asset is undervalued relative to its momentum, providing the investor with a significant margin of safety upon purchase.

Competing companies

SMMT (Summit Therapeutics plc) - Growth-Adjusted Payback Ratio|PEG Multiple MRNA (Moderna Corp)|Growth-Adjusted Market Cap to Net Income SutroVax (PCVX)|TARS - Price/Earnings to Growth Ratio|MCRB (serestherapeutics.com) - Growth-Adjusted P/E Ratio|SPRO: PEG Multiple|Market Cap to Earnings and Growth Ratio SCYX (SCYNEXIS)|ANTX (AN2 Therapeutics Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate PolyPid Limited PYPD|PEG Multiple LSB|Price/Earnings to Growth Multiple iterumtx.com ITRM|BiomX - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio SNGX (Soligenix Inc)|60 Degrees Pharma - PEG Multiple|Growth-Adjusted Market Cap to Net Income Oragenics Inc. OGEN|OpGen, Inc. (OPGN) - Price/Earnings to Growth Ratio